Comparative Pharmacology
Head-to-head clinical analysis: HALOTEX versus NYSTOP.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HALOTEX versus NYSTOP.
HALOTEX vs NYSTOP
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Halotex (haloprogin) is a topical antifungal agent that disrupts fungal cell membrane permeability and inhibits ergosterol synthesis, leading to cell death.
Nystatin binds to ergosterol in fungal cell membranes, forming pores that disrupt membrane integrity, leading to leakage of intracellular ions and cell death.
Apply topically twice daily for 2-4 weeks; tinea pedis may require up to 6 weeks.
Apply a thin layer to affected area 2-3 times daily or as directed. Nystatin is not absorbed systemically; topical use only.
None Documented
None Documented
Not well characterized; estimated terminal half-life approximately 24-48 hours based on limited data.
Not applicable for systemic pharmacokinetics due to minimal absorption; local half-life on mucosal surfaces is not defined. For intravenous administration (not approved), the terminal half-life is approximately 2-4 hours, but this route is not clinically used.
Primarily fecal (biliary) as unchanged drug and metabolites; negligible renal excretion (<1%).
Nystatin is not absorbed from the gastrointestinal tract or intact skin/mucous membranes; when administered topically or orally, it is excreted almost entirely in feces as unchanged drug (>99%). Less than 1% is excreted renally if ingested. No quantified biliary excretion reported.
Category C
Category C
Antifungal
Antifungal